These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33211759)

  • 1. Alpha-1 blocker use increased risk of subsequent renal cell carcinoma: A nationwide population-based study in Taiwan.
    Sung SY; Le TTH; Chen JH; Hsieh TF; Hsieh CL
    PLoS One; 2020; 15(11):e0242429. PubMed ID: 33211759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthyroidism is not a significant risk of benign prostatic hyperplasia: A nationwide population-based study.
    Man KM; Chen KB; Chen HY; Chiang JH; Su YC; Man SS; Xie DD; Wang Y; Zhang ZQ; Bi LK; Zhang T; Yu DX; Chen WC
    Medicine (Baltimore); 2018 Sep; 97(39):e12459. PubMed ID: 30278528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower urinary tract symptoms-Benign prostatic hyperplasia may increase the risk of subsequent inguinal hernia in a Taiwanese population: A nationwide population-Based cohort study.
    Wu YH; Juan YS; Shen JT; Wang HS; Jhan JH; Lee YC; Geng JH
    PLoS One; 2020; 15(6):e0234329. PubMed ID: 32511262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of alpha-1-adrenergic antagonist use with the risk of gout development in benign prostatic hyperplasia patients: a population-based cohort study.
    Hsu WH; Lai JN; Lin CL; Loh CH; Huang HK; Huang LK
    Fam Pract; 2022 May; 39(3):426-431. PubMed ID: 34964888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
    Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
    Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
    Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
    BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia.
    Shih HJ; Huang CJ; Lin JA; Kao MC; Fan YC; Tsai PS
    Prostate; 2018 Feb; 78(2):113-120. PubMed ID: 29119583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?
    Fusco F; Arcaniolo D; Creta M; Piccinocchi G; Arpino G; Laringe M; Piccinocchi R; Longo N; Verze P; Mangiapia F; Imperatore V; Mirone V
    World J Urol; 2015 May; 33(5):685-9. PubMed ID: 25491675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
    Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
    BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-1 Adrenergic-Antagonist Use Increases the Risk of Sleep Apnea: A Nationwide Population-Based Cohort Study.
    Su PL; Lin WK; Lin CY; Lin SH
    J Clin Sleep Med; 2019 Nov; 15(11):1571-1579. PubMed ID: 31739846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Alpha1-Adrenoceptor Antagonists and Increased Risk of Open-Angle Glaucoma: A Nationwide Population-Based Cohort Study.
    Lin HZ; Hsieh TC; Wu JL; He MS; Lee YC
    Invest Ophthalmol Vis Sci; 2020 Aug; 61(10):15. PubMed ID: 32766746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased One-Year Recurrent Ischemic Stroke after First-Ever Ischemic Stroke in Males with Benign Prostatic Hyperplasia.
    Cheng CG; Chu H; Lee JT; Chien WC; Cheng CA
    Int J Environ Res Public Health; 2020 Jul; 17(15):. PubMed ID: 32722374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study.
    Peng YH; Huang CW; Liao WC; Chen HJ; Yin MC; Huang YM; Wu TN; Ho WC
    BMJ Open; 2017 Jun; 7(6):e015581. PubMed ID: 28645971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma.
    Parker WP; Lohse CM; Zaid HB; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
    Urol Oncol; 2017 Jan; 35(1):36.e1-36.e6. PubMed ID: 27687543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug or symptom-induced depression in men treated with alpha 1-blockers for benign prostatic hyperplasia? A nested case-control study.
    Clifford GM; Farmer RD
    Pharmacoepidemiol Drug Saf; 2002; 11(1):55-61. PubMed ID: 11998552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study.
    Hsieh TF; Yang YW; Lee SS; Lin TH; Liu HH; Tsai TH; Chen CC; Huang YS; Lee CC
    PLoS One; 2015; 10(3):e0119694. PubMed ID: 25803433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
    Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of benign prostatic hyperplasia on the development of spine, hip, and wrist fractures.
    Yang SC; Chiu YC; Liu PH; Hsieh TJ; Kao YH; Tu YK
    Osteoporos Int; 2019 May; 30(5):1043-1049. PubMed ID: 30706096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-alpha-reductase inhibitors and the risk of diabetes mellitus: A nationwide population-based study.
    Lee SS; Yang YW; Tsai TH; Kuo YH; Chuang HY; Lee CC; Hsieh TF
    Prostate; 2016 Jan; 76(1):41-7. PubMed ID: 26390988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.